Teva Pharmaceutical Industries (NASDAQ:TEVA) and Regeneron Pharmaceuticals (NASDAQ:REGN) enter into a global agreement to develop and commercialize Regeneron's fasinumab, currently in Phase 3 for osteoarthritis pain and Phase 2 for chronic lower back pain.
Fasinumab is a fully human monoclonal antibody that targets Nerve Growth Factor (NGF), a protein that plays a key role in the regulation of pain signaling
LOL....Keeps getting better
Senior HR Business Consultant- Arena Pharma June 2016 – Present
Vice President; Global Human Resources & Corporate Administration
May 2014 – June 2016